Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.

Foresite Capital

Apeiron Investment Group is the family office and private investment firm of entrepreneur and investor Christian Angermayer. With more than USD 2.5 billion under management and over 50 people across five international locations, Apeiron focuses on Life Sciences, FinTech & Crypto, FutureTech, and Experiences, Hospitality & Happiness. Apeiron has a global approach and deploys its capital across the entire company lifecycle, from founding companies in-house, seed/start-up investments, to large-scale investments in listed companies.

Apeiron Investment Group

IPGL

Grok Ventures is an Australia based fund investing globally in technology enabled climate companies and infrastructure.

Grok Ventures

Explorer Equity Group (“EEG”) is a private equity firm that invests in global emerging trends that have the potential to transform the world.

Explorer Equity Group

Longevity Vision Fund is a $100M investment fund dedicated to making longevity affordable and accessible to all. The fund accelerates longevity breakthroughs by investing in companies that develop technologies, products, and services that extend healthy human lifespans and overcome the negative effects of aging Longevity Vision Fund provides Seed to Series C funding to biotech and life extension-focused companies that have demonstrated affordable longevity potential and vision of milestones driving up the value of the company and market validation.

Longevity Vision Fund

Oryx Ventures is a venture capital firm that focuses on investing in growth stage technology companies based out of the USA.

Oryx Ventures

Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.

Formic Ventures

Juvenescence

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Based in Hong Kong, Insilico Medicine focuses on three areas of drug discovery and development: disease target identification, generation of synthetic biology and novel molecules data, and predicting clinical trial outcomes.&nbsp;
 
 
 The company's key focus area is anti-aging interventions; however, there is also a therapeutic focus on areas such as oncology, dermatology, metabolic diseases, neuroscience, and rare diseases. Nearly a quarter of the company&rsquo;s R&amp;D budget is committed toward aging-related diseases.&nbsp;
 
 
 The company collaborates with pharma companies and also has its own pipeline of small molecules targeting many disease areas, which the company aims to license to pharma players later.&nbsp;
 
 
 In a landmark achievement, Insilico announced in November 2021 that it initiated its first in-human clinical trial of its lead drug compound ISM001-055 (INS018_055) for idiopathic pulmonary fibrosis (IPF). It is reportedly the first-ever AI-discovered drug to be tested on a human. Two years earlier, the company announced that the compound was discovered by the company&rsquo;s AI platform in just 46 days compared to the two- to three-year timespan required for traditional drug discoveries. It also completed the entire preclinical stage, from the earliest stages of identifying potential targets, in a record time of 18 months. In February 2023, the candidate became the first to receive an 
 <a href="https://www.genengnews.com/artificial-intelligence/insilico-gains-fdas-first-orphan-drug-designation-for-ai-candidate/">
 orphan drug designation
 </a>
 from the FDA and initiated a global 
 <a href="https://sp-edge.com/updates/19798">
 Phase II clinical trial
 </a>
 in June 2023.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company entered partnerships with several China- and US-based companies, including NVIDIA (May 2024) to launch the Nach0 language processing tool for biomedical and chemical tasks; 
 <a href="https://sp-edge.com/updates/28807">
 InvoX Pharma
 </a>
 (April 2024) to identify potential uses for invoX&rsquo;s pipeline using Insilico&rsquo;s PandaOmics AI platform; 
 <a href="https://sp-edge.com/updates/21805">
 Exelixis
 </a>
 (September 2023) to develop and commercialize an AI-generated cancer treatment, ISM3091; 
 <a href="https://en.prnasia.com/story/archive/3487576_AE87576_0?utm_source=cleartime-customer&utm_medium=email&fbclid=IwAR3GoL4_NIvdPGv5a-d7QgZkNh9pgJSKYzbFawltIe3Jv17rn1ca72ARUR0">
 4B Technologies
 </a>
 (August 2021) to develop innovative small-molecule therapies for neurological diseases; 
 <a href="https://www.prnewswire.com/news-releases/insilico-medicine-announces-an-ai-driven-protac-rd-collaboration-with-arvinas-301351106.html?tc=eml_cleartime&fbclid=IwAR0AQIMqXebdleapMxubR0OqkkSll_CnglrSUa2TuRWXbXliLoHZGOdQRrE">
 Arvinas
 </a>
 (August 2021) to demonstrate the potential of combining AI with proteolysis-targeting chimera (PROTACs); 
 <a href="https://www.eurekalert.org/news-releases/777014">
 Teva Branded Pharmaceutical
 </a>
 (June 2021); and 
 <a href="https://www.eurekalert.org/news-releases/532850">
 APRINOIA Therapeutics
 </a>
 (December 2020).
 
 
 In January 2022, insilico collaborated with 
 <a href="https://www.prnewswire.com/news-releases/fosun-pharma-and-insilico-medicine-announce-a-strategic-ai-driven-drug-discovery-and-development-collaboration-to-jointly-advance-multiple-targets-301457569.html?tc=eml_cleartime">
 Fosun Pharma
 </a>
 to use AI technology in drug discovery and development. The companies completed the second preclinical candidate compound (PCC) for treating solid tumors in 
 <a href="https://sp-edge.com/updates/31232">
 July 2024
 </a>
 .
 
 
 The company also collaborated with big pharma companies 
 <a href="https://www.eurekalert.org/news-releases/490685">
 Pfizer
 </a>
 (January 2020) to utilize Insilico's machine-learning technology and proprietary Pandomics Discovery Platform and 
 <a href="https://sp-edge.com/updates/14409">
 Sanofi 
 </a>
 (November 2022) to develop novel therapeutics across six new targets.
 
</div>

Longevity Tech

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD).

Morphoceuticals is a biotechnology platform establishing a basis for limb regeneration and the discovery of regenerative interventions. It focuses on the understanding of the biophysical mechanisms that implement decision-making during complex pattern regulation and utilizes bioelectric dynamics to change developmental patterning and spur regeneration in organisms that do not regenerate tissues or organs. It helps medical researchers to treat complicated health states through limb regeneration, improving amputation stump health, promoting organ regeneration, and the treatment of channelopathies.

MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments using clinical biomarkers.

Souvien Therapeutics is a biotechnology company focused on developing therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.

BYOMass is developing therapeutics to modulate the central control of metabolism associated with aging and age-related chronic illnesses.

BHB Therapeutics is developing novel approaches to induce a state of ketosis, which may have protective effects against age-related disease.

AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.

Napa Therapeutics is a biotechnology company focused on a novel target linked to one of the fundamental processes of aging. A privately held British Virgin Islands company with an office in the Isle of Man, Napa is developing small molecule drugs to address this target.

FoxBio is a developer of a small molecules techniques intended to reduce senescent cells in human bodies. The company's techniques targets the pro-survival pathways of senescent cells to remove them from the body, enabling patients to have multiple health benefits and delay the onset of age related diseases.

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure. The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging. Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.

<div>Juvenescence is a biotech company that focuses on cellular regeneration and advanced nutritional and veterinary solutions targeting aging and related diseases. The company also manufactures and offers Cognitive Switch on a subscription basis, which contains a proprietary C8 ketone di-ester that is claimed to help boost focus and mental clarity.</div>

Juvenescence joins Banco Português de Fomento and 200M Fund in co-investment in Chrysea Laboratories

LyGenesis

Prime Movers Lab

Morphoceuticals

MDI Therapeutics

Souvien Therapeutics

BYOMass

BHB Therapeutics

<div>
 
 Juvenescence is a biotech company that focuses on cellular regeneration and advanced nutritional and veterinary solutions targeting aging and related diseases. The company also manufactures and offers Cognitive Switch on a subscription basis, which contains a proprietary C8 ketone di-ester that is claimed to help boost focus and mental clarity.
 
 
 
 
 As of October 2023, the company&rsquo;s 10 leading programs were in early clinical stages. These technologies and targets range from regenerative medicine, youthful cell signaling, and inflammation reversal to aging heart and brain improvement and cellular membrane restoration.&nbsp;
 
 
 
 
 LyGenesis, the company&rsquo;s program in the most advanced stage of clinical development (Phase II) out of the pipeline, is a hepatocyteto cell therapy in lymph nodes to restore function in end-stage liver disease. This is claimed to allow a single donated liver to act as the seed for dozens of transplants using outpatient endoscopy to engraft the cells. These allogeneic hepatocytes engraft, vascularize, and perform all of the functions typical to liver tissue, enabling them to rescue patients from ESLD.
 
 
 
 
 The other products in its pipeline (as of October 2023) are targeted toward fibrosis, congestive heart failure, chronic kidney disease, heart failure, epilepsy, rheumatoid arthritis, type I diabetes, cognitive impairment, and neurological areas.&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 The company raised an undisclosed amount in a Series B funding round in 2019 led by IDO Investments.&nbsp;
 
 
 
 
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

Juvenescence

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless